How should a rash in a pregnant woman be evaluated and managed?

Evaluation and Management of Rash in Pregnancy

A pregnant woman presenting with a rash requires immediate assessment to distinguish between benign pregnancy-specific dermatoses and potentially life-threatening conditions like intrahepatic cholestasis of pregnancy (ICP) or pemphigoid gestationis, which carry significant fetal risks including stillbirth and prematurity.

Initial Clinical Assessment

Key Historical Features to Elicit

• Timing of onset: Second vs third trimester onset narrows differential
• Pruritus characteristics:
  • Generalized pruritus affecting palms/soles, worse at night without primary rash → suspect ICP
  • Pruritus with periumbilical vesicles/bullae → suspect pemphigoid gestationis
  • Pruritus with urticarial papules in abdominal striae, sparing umbilicus → polymorphic eruption of pregnancy (PEP)
  • Pruritus with eczematous lesions on face, neck, flexures → atopic eruption of pregnancy (AEP)
• Distribution pattern: Abdominal striae vs periumbilical vs generalized
• Presence of excoriations: May indicate severe pruritus from ICP rather than primary dermatosis 1, 2, 3

Physical Examination Findings

Morphology and distribution are diagnostic:

• Vesicles/bullae starting periumbilically → pemphigoid gestationis
• Urticarial papules/plaques in striae, umbilicus spared → PEP
• Excoriations without primary rash, palmar/plantar involvement → ICP
• Eczematous patches on flexures → AEP 2, 4

Diagnostic Testing Algorithm

For Pruritus WITHOUT Primary Rash (ICP suspected):

1. Serum total bile acids (diagnostic threshold ≥10 μmol/L, severe disease ≥100 μmol/L)
2. Liver function tests (ALT, AST)
3. Consider viral hepatitis serologies if risk factors present 1

For Vesiculobullous Eruption (Pemphigoid Gestationis suspected):

1. Direct immunofluorescence of perilesional skin (linear C3 deposition at basement membrane zone)
2. Indirect immunofluorescence or ELISA for anti-BP180 antibodies 5

For Urticarial/Papular Eruptions:

• Clinical diagnosis typically sufficient for PEP and AEP
• No specific laboratory testing required 2, 3

Management by Diagnosis

Intrahepatic Cholestasis of Pregnancy (HIGHEST FETAL RISK)

This condition poses significant risk for stillbirth and requires aggressive management.

Treatment:

• Ursodeoxycholic acid (UDCA) is first-line therapy 1, 2
• For refractory pruritus, add sequentially:
  • Cholestyramine 4-16 g daily (divided doses, separated from other medications by 2 hours)
  • Rifampin 300-600 mg daily
  • Antihistamines for symptomatic relief 6, 1

Monitoring:

• Monitor PT/INR due to vitamin K malabsorption risk with cholestyramine
• Supplement vitamin K if PT prolonged 6

Delivery timing based on bile acid levels:

• Bile acids ≥100 μmol/L: Deliver at 36 0/7 weeks (strong recommendation due to substantially increased stillbirth risk)
• Bile acids <100 μmol/L: Deliver between 36 0/7 and 39 0/7 weeks
• Administer antenatal corticosteroids if delivering <37 weeks 1

Pemphigoid Gestationis (MODERATE FETAL RISK)

Associated with prematurity and small-for-gestational-age infants; 45% of neonates develop transient lesions.

Treatment:

• Prednisolone is first-line (90% inactivated by placenta, minimizing fetal exposure)
• Doses typically 5-300 mg daily depending on severity
• Avoid betamethasone/dexamethasone (cross placenta more readily)
• Azathioprine can be added as steroid-sparing agent if needed (low teratogenicity risk, widely used in pregnancy)
• IVIg is safe for severe, refractory cases 5

Neonatal considerations:

• Inform neonatology team
• Neonatal lesions resolve within 4 weeks spontaneously or with mild topical corticosteroids 5

Polymorphic Eruption of Pregnancy (NO FETAL RISK)

Maternal discomfort only; no adverse fetal outcomes.

Treatment:

• Topical corticosteroids (moderate to high potency)
• Oral antihistamines for pruritus
• Oral corticosteroids (prednisolone) for severe cases
• Condition typically resolves postpartum 2, 7

Atopic Eruption of Pregnancy (NO FETAL RISK)

Most common pruritic disorder in pregnancy; maternal symptoms only.

Treatment:

• Emollients and skin barrier repair
• Topical corticosteroids for eczematous lesions
• Oral antihistamines
• Prednisolone for severe flares 2, 7

Critical Pitfalls to Avoid

1. Never dismiss generalized pruritus without rash as "normal pregnancy itching" - always check bile acids to exclude ICP 1, 3

2. Do not delay delivery in ICP with bile acids ≥100 μmol/L - stillbirth risk increases substantially at 36 weeks 1

3. Avoid betamethasone/dexamethasone for pemphigoid gestationis - use prednisolone which is largely inactivated by placenta 5

4. Monitor PT/INR in patients taking cholestyramine for ICP - vitamin K malabsorption can cause coagulopathy 6

5. Inform neonatology when mother has pemphigoid gestationis - 45% of neonates develop transient lesions requiring monitoring 5

Medications Safe in Pregnancy for Dermatoses

Safe options:

• Prednisolone (preferred corticosteroid)
• Azathioprine (for pemphigoid gestationis)
• UDCA (for ICP)
• Topical corticosteroids
• Antihistamines
• IVIg 5, 6, 5, 1

Avoid:

• Mycophenolate mofetil
• Methotrexate
• Cyclophosphamide
• Rituximab (avoid pregnancy for 1 year after use) 5